Agios hit a setback for Tibsovo in Europe this year however after the EMA rejected the marketing application for the drug. Servier is paying $1.8 billion upfront for the oncology assets ...
Servier is already in the process of transforming ... The latter brought in acute myeloid leukaemia (AML) and cholangiocarcinoma therapy Tibsovo (ivosidenib), which was approved as a first-line ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback